M13/nLNP, a lipid nanoparticle-encapsulated drug, alleviated clinical signs of IBD, reduced intestinal mucosal ulcers, and decreased TNF-α and IL-6 mRNA levels in experiments on IL-10KO mice. This evidence concerns the gene IL6 and irritable bowel syndrome.